FilingSEC EDGAR8-K
Cocrystal Pharma Completes Dosing in Phase 1b Study for Norovirus Candidate CDI-988
· SEC accepted
StagePhase 1b
Filing content
Cocrystal Pharma announced the completion of dosing for the last subject in its Phase 1b study of CDI-988, with preliminary efficacy results expected in late 2026 or early 2027.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…